JSM 2011 Online Program
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Activity Details
|
|||
517 * | Wed, 8/3/2011, 10:30 AM - 12:20 PM | CC-D235 | |
Topics in Group Sequential Designs and Interim Analysis — Contributed Papers | |||
Biopharmaceutical Section | |||
Chair(s): Samir Lababidi, U.S. Food and Drug Administration | |||
10:35 AM | Software Applications to Group Sequential Trial Design and Monitoring — Li Zhu, Amgen Inc. ; Liyun Ni, Amgen Inc. ; Bin Yao, Amgen Inc. | ||
10:50 AM | Considerations on Decision Rules for Futility Based on Multiple Studies — Annpey Pong, Merck & Co., Inc. ; Jun Zhao, Merck & Co., Inc. | ||
11:05 AM | Optimal Designs with Futility Stopping for Diagnostic Imaging Studies — Aida Aydemir, Bayer HealthCare Pharmaceuticals Inc. ; Igor Zurbenko, The State University of New York at Albany ; Daniel Haverstock, Bayer HealthCare Pharmaceuticals Inc. ; Christoph Gerlinger , Bayer Schering Pharma AG | ||
11:20 AM | Group Sequential Tests of Futility: The Relationship Between Type II Error Spending and Conditional Power Approaches — Thomas W. Dobbins, Merck & Co., Inc. | ||
11:35 AM | Futility Analysis Approaches in Clinical Equivalence Trials — Christine K. Gause, Merck Research Laboratories | ||
11:50 AM | Blind Review of Planned Analyses for Clinical Trials — Lan Liu, Quintiles Inc. ; John Schollenberger, Quintiles Inc. | ||
12:05 PM | Floor Discussion |
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.